{"id":5052,"date":"2025-10-22T15:30:00","date_gmt":"2025-10-22T15:30:00","guid":{"rendered":"https:\/\/oncopeptides.com\/mfn_news\/oncopeptides-bjuder-in-till-capital-markets-update-med-ledande-globala-experter-inom-multipelt-myelom\/"},"modified":"2026-04-09T15:26:46","modified_gmt":"2026-04-09T15:26:46","slug":"oncopeptides-bjuder-in-till-capital-markets-update-med-ledande-globala-experter-inom-multipelt-myelom","status":"publish","type":"mfn_news","link":"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-bjuder-in-till-capital-markets-update-med-ledande-globala-experter-inom-multipelt-myelom\/","title":{"rendered":"Oncopeptides bjuder in till Capital Markets Update med ledande globala experter inom multipelt myelom"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p class=\"mfn-wp-retain\"><strong>Stockholm, 22 oktober 2025 \u2013 Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) kommer att h\u00e5lla ett evenemang riktat mot kapitalmarknaden \u2013 Capital Markets Update \u2013 den 13 november 2025 kl. 09:00 till 12:00 CET. Evenemanget kommer att s\u00e4ndas live fr\u00e5n Stockholm, och \u00e4mnar ge aktie\u00e4gare och potentiella investerare en djupg\u00e5ende inblick i f\u00f6retagets strategiska riktning och dess v\u00e4xande roll i det snabbt f\u00f6r\u00e4nderliga behandlingslandskapet f\u00f6r multipelt myelom.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p class=\"mfn-wp-retain\">Halvdagen kommer att inneh\u00e5lla presentationer och diskussioner med en grupp av framst\u00e5ende internationella experter, som ger ett kliniskt, vetenskapligt och marknadsperspektiv fr\u00e5n Europa, Japan och USA.<\/p>\n<p class=\"mfn-wp-retain\"><strong>Bland h\u00f6jdpunkterna finns:<\/strong><\/p>\n<ul>\n<li><strong>Prof. Dr. Sebastian Theurich<\/strong>, LMU Universitetssjukhuset i M\u00fcnchen \u2013 <em>&#8221;Multipelt myelom och det ouppfyllda medicinska behovet.&#8221;<\/em><\/li>\n<li><strong>Dr. Mar\u00eda-Victoria Mateos<\/strong>, University of Salamanca \u2013 &#8221;<em>Kliniska reflektioner fr\u00e5n verkliga erfarenheter av Pepaxti.&#8221;<\/em><\/li>\n<li><strong>Dr. Claudio Cerchione<\/strong>, IRST, IRCCS, Italien, och <strong>Prof. Dr. med. Klaus Fenchel<\/strong>, Tyskland \u2013 &#8221;<em>Paneldiskussion om det europeiska behandlingslandskapet och real-world data.&#8221;<\/em><\/li>\n<li><strong>Prof. Shinsuke Iida<\/strong>, Nagoya City University (Japan) \u2013 &#8221;<em>Det japanska landskapet f\u00f6r multipelt myelom.&#8221;<\/em><\/li>\n<li><strong>Prof. Paul G. Richardson<\/strong>, Dana-Farber Cancer Institute \/ Harvard Medical School (USA) \u2013 &#8221;<em>PDC-plattformens potential p\u00e5 den amerikanska marknaden.&#8221;<\/em><\/li>\n<\/ul>\n<p class=\"mfn-wp-retain\">Eventet kommer ocks\u00e5 att inneh\u00e5lla presentationer fr\u00e5n <strong>Dr. Bj\u00f6rn Odlander<\/strong>, grundare och Managing Partner f\u00f6r HealthCap och Oncopeptides vd <strong>Sofia Heigis<\/strong>, som kommer att dela insikter om Oncopeptides aff\u00e4rsutsikter, tillv\u00e4xtstrategi och investeringscase.<\/p>\n<p class=\"mfn-wp-retain\"><strong>S\u00e5 h\u00e4r deltar du<\/strong><br \/>\nEvenemanget kommer att streamas live fr\u00e5n Inderes studio i Stockholm och senare finnas tillg\u00e4ngligt on-demand p\u00e5 <a href=\"https:\/\/www.oncopeptides.com\" target=\"_blank\" rel=\"noopener\">www.oncopeptides.com<\/a>.<\/p>\n<p class=\"mfn-wp-retain\"><strong>F\u00f6r att registrera dig, f\u00f6lj <\/strong><strong><a href=\"https:\/\/oncopeptides.events.inderes.com\/cmu-2025\/register\" target=\"_blank\" rel=\"noopener\">den h\u00e4r l\u00e4nken<\/a><\/strong><strong>.<\/strong><br \/>\n<strong><br \/>\n<\/strong><br \/>\n<strong>\u00a0<\/strong><br \/>\n<strong>Fullst\u00e4ndig agenda<\/strong><br \/>\n<em>Evenemanget kommer att h\u00e5llas p\u00e5 engelska. Alla tider i CET. Dagordningen kan komma att \u00e4ndras.<\/em><br \/>\n<em>\u00a0<\/em><br \/>\n<strong>09.00 \u2013 09.03 | Welcome<\/strong><br \/>\nSpeaker: <strong>David <\/strong><em><strong>Augustsson<\/strong><\/em><strong>,<\/strong> Director of IR, Oncopeptides.<\/p>\n<p class=\"mfn-wp-retain\"><strong>09.03-09.20 | Bringing Hope through Science<\/strong><br \/>\nSpeaker: <strong>Sofia Heigis<\/strong>, CEO, Oncopeptides.<\/p>\n<p class=\"mfn-wp-retain\"><strong>09.20-09.30 | Owner\u2019s perspective<\/strong><br \/>\nSpeaker: <strong>Dr.<\/strong> <strong>Bj\u00f6rn Odlander,<\/strong> founder and managing partner, HealthCap.<\/p>\n<p class=\"mfn-wp-retain\"><strong>09.30-9.55 | Keynote 1:\u00a0Multiple myeloma and the unmet medical need<\/strong><br \/>\nSpeaker: <strong>Prof. Dr. Sebastian Theurich.<\/strong><br \/>\nDescription: An introduction to multiple myeloma and the treatment landscape, emphasizing the need for new treatments in the 4L+ stage.<\/p>\n<p class=\"mfn-wp-retain\"><strong>9.55-10.00 | From Need to Treatment \u2013 A Clinician\u2019s Reflection<\/strong><br \/>\nSpeaker: <strong>Dr.<\/strong> <strong>Mar\u00eda\u2011Victoria\u00a0Mateos.<\/strong><br \/>\nDescription: Dr. Mateos shares her perspective on the evolving treatment landscape and the clinical relevance of Pepaxti in addressing unmet needs in relapsed and refractory multiple myeloma.<\/p>\n<p class=\"mfn-wp-retain\"><strong>10.00-10.25 | Conversation:\u00a0Relapsed, refractory multiple myeloma \u2013 clinical experience with Pepaxti<\/strong><br \/>\nSpeakers: <strong>Dr.<\/strong> <strong>Claudio Cerchione<\/strong>, <strong>Prof. Dr. med.<\/strong> <strong>Klaus Fenchel<\/strong>.<br \/>\nDescription: A conversation on the European multiple myeloma landscape and the treatment challenges facing today\u00b4s healthcare practitioners.<\/p>\n<p class=\"mfn-wp-retain\"><strong>10.25-10.35 | BREAK<\/strong><\/p>\n<p class=\"mfn-wp-retain\"><strong>10.35-10.45 | Keynote 2: The Japanese Multiple Myeloma landscape<\/strong><br \/>\nSpeaker: <strong>Prof. Shinsuke Iida.<\/strong><\/p>\n<p class=\"mfn-wp-retain\"><strong>10.45-10.55 | Keynote 3: The potential of the PDC platform in the U.S.<\/strong><br \/>\nSpeaker: <strong>Prof. Paul Richardson.<\/strong><\/p>\n<p class=\"mfn-wp-retain\"><strong>10.55-11.30 | Oncopeptides as an investment case \u2013 where do we go from here?<\/strong><br \/>\nSpeaker: <strong>Sofia Heigis,<\/strong> CEO, Oncopeptides.<\/p>\n<p class=\"mfn-wp-retain\"><strong>11.30-11.45 | Questions and Answers from investors<\/strong><br \/>\nAll in-person participants.<\/p>\n<p class=\"mfn-wp-retain\"><strong>11.45-11.50 | Closing remarks<\/strong><br \/>\nSpeaker: <strong>Sofia Heigis,<\/strong> CEO, Oncopeptides.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-ad2e6a7e9211\">\n<p class=\"mfn-wp-retain\"><strong class=\"mfn-heading-1\">F\u00f6r ytterligare information kontakta:<\/strong><br \/>\nDavid Augustsson, Kommunikations- och IR-chef, Oncopeptides AB (publ)<br \/>\nE-post: <a href=\"mailto:%20ir@oncopeptides.com\" target=\"_blank\" rel=\"noopener\">ir@oncopeptides.com<\/a><br \/>\nMobil: +46 76 229 38 68<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-05abf943815f\">\n<p class=\"mfn-wp-retain\"><strong class=\"mfn-heading-1\">Om Oncopeptides<\/strong><br \/>\nOncopeptides \u00e4r ett svenskt biotechbolag inriktat p\u00e5 forskning, utveckling och kommersialisering av riktade terapier f\u00f6r sv\u00e5rbehandlade cancersjukdomar.<\/p>\n<p class=\"mfn-wp-retain\">Bolaget anv\u00e4nder sin patenterade PDC-plattform f\u00f6r att utveckla peptidl\u00e4nkade l\u00e4kemedel som snabbt och selektivt levererar cellgifter in i cancerceller. Bolagets flaggskeppsl\u00e4kemedel kommersialiseras f\u00f6r n\u00e4rvarande i Europa, med partnerskapsavtal f\u00f6r bland annat Sydkorea, Mellan\u00f6stern och Afrika.<\/p>\n<p class=\"mfn-wp-retain\">Oncopeptides utvecklar flera nya l\u00e4kemedelskandidater baserat p\u00e5 sina tv\u00e5 patenterade teknikplattformar PDC och SPiKE.<\/p>\n<p class=\"mfn-wp-retain\">Bolaget grundades \u00e5r 2000, har ca 80 anst\u00e4llda och verksamhet i Sverige, Tyskland, \u00d6sterrike, Italien och Spanien. Oncopeptides \u00e4r noterat p\u00e5 Nasdaq Stockholm med f\u00f6rkortningen ONCO.<\/p>\n<p class=\"mfn-wp-retain\">F\u00f6r mer information, se <a href=\"http:\/\/www.oncopeptides.com\/sv\/\" target=\"_blank\" rel=\"noopener\">www.oncopeptides.com<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p class=\"mfn-wp-retain\"><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><br \/>\n<a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/2c22e97f-c954-4e62-866d-cf1b8c89c0bd\/oncopeptides-bjuder-in-till-capital-markets-update-med-ledande-globala-experter-inom-multipelt-myelom.pdf\" target=\"_blank\" rel=\"noopener\">Oncopeptides bjuder in till Capital Markets Update med ledande globala experter inom multipelt myelom<\/a><\/p>\n<\/div>\n<script>\n                Array.prototype.slice.call(document.querySelectorAll(\".mfn-footer.mfn-attachment\")).forEach(function (el) { el.remove() });\n            <\/script>\n        <div class=\"mfn-attachments-container\"><div class=\"mfn-attachment mfn-file-type-pdf mfn-primary\"><a class=\"mfn-attachment-link\" target=\"_blank\" href=\"https:\/\/storage.mfn.se\/2c22e97f-c954-4e62-866d-cf1b8c89c0bd\/oncopeptides-bjuder-in-till-capital-markets-update-med-ledande-globala-experter-inom-multipelt-myelom.pdf\" rel=\"noopener\"><span class=\"mfn-attachment-icon\"><img decoding=\"async\" src=\"https:\/\/storage.mfn.se\/2c22e97f-c954-4e62-866d-cf1b8c89c0bd\/oncopeptides-bjuder-in-till-capital-markets-update-med-ledande-globala-experter-inom-multipelt-myelom.pdf?type=jpg\"><\/span>Oncopeptides bjuder in till Capital Markets Update med ledande globala experter inom multipelt myelom<\/a><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Stockholm, 22 oktober 2025 \u2013 Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) kommer att h\u00e5lla ett evenemang riktat mot kapitalmarknaden \u2013 Capital Markets Update \u2013 den 13 november 2025 kl. 09:00 till 12:00 CET. Evenemanget kommer att s\u00e4ndas live fr\u00e5n Stockholm, och \u00e4mnar ge aktie\u00e4gare och potentiella investerare en djupg\u00e5ende inblick i f\u00f6retagets strategiska riktning och dess v\u00e4xande roll i det snabbt f\u00f6r\u00e4nderliga behandlingslandskapet f\u00f6r multipelt myelom<\/p>\n","protected":false},"featured_media":0,"template":"","news_categories":[365],"mfn-news-tag":[278,174,171,180],"class_list":["post-5052","mfn_news","type-mfn_news","status-publish","hentry","news_categories-investerare","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn_news\/5052","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media?parent=5052"}],"wp:term":[{"taxonomy":"news_categories","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/news_categories?post=5052"},{"taxonomy":"mfn-news-tag","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn-news-tag?post=5052"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}